<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="5565"><DrugName>nolatrexed</DrugName><DrugNamesKey><Name id="42757461">Thymitaq</Name><Name id="42757462">nolatrexed</Name></DrugNamesKey><DrugSynonyms><Name><Value>AG-337</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Thymitaq</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>nolatrexed</Value><Types><Type>INN</Type></Types></Name><Name><Value>ZX-337</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>nolatrexed (intravenous), EXIMIAS</Value></Name><Name><Value>152946-68-4</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>147149-76-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="26488">Agouron Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="26148">YM BioSciences USA</Company><Company id="26178">F Hoffmann-La Roche AG</Company><Company id="26488">Agouron Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="5565" type="Drug"><TargetEntity id="194638" type="siDrug">Nolatrexed dihydrochloride</TargetEntity></SourceEntity><SourceEntity id="26148" type="Company"><TargetEntity id="5035561330" type="organizationId">YM Biosciences USA Inc</TargetEntity></SourceEntity><SourceEntity id="26178" type="Company"><TargetEntity id="5000075049" type="organizationId">F Hoffmann La Roche AG</TargetEntity></SourceEntity><SourceEntity id="26488" type="Company"><TargetEntity id="4295908789" type="organizationId">Agouron Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"></TargetEntity><TargetEntity id="88673" type="ORPHANET"></TargetEntity><TargetEntity id="-1116061312" type="omicsDisease"></TargetEntity><TargetEntity id="1973" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="623" type="ciIndication"><TargetEntity id="C76.0" type="ICD10"></TargetEntity><TargetEntity id="10067821" type="MEDDRA"></TargetEntity><TargetEntity id="D006258" type="MeSH"></TargetEntity><TargetEntity id="-545944758" type="omicsDisease"></TargetEntity><TargetEntity id="1148" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="755" type="ciIndication"><TargetEntity id="C34" type="ICD10"></TargetEntity><TargetEntity id="10062042" type="MEDDRA"></TargetEntity><TargetEntity id="D008175" type="MeSH"></TargetEntity><TargetEntity id="-243902424" type="omicsDisease"></TargetEntity><TargetEntity id="611" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="767" type="ciIndication"><TargetEntity id="C18" type="ICD10"></TargetEntity><TargetEntity id="10009944" type="MEDDRA"></TargetEntity><TargetEntity id="D003110" type="MeSH"></TargetEntity><TargetEntity id="-729056112" type="omicsDisease"></TargetEntity><TargetEntity id="593" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="276">Prostate tumor</Indication><Indication id="623">Head and neck tumor</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication><Indication id="755">Lung tumor</Indication><Indication id="767">Colon tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="372">Thymidylate synthase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="572">Radiochemosensitizer</Action><Action id="553">Folate synthesis inhibitor</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2017-11-29T15:57:38.000Z</LastModificationDate><ChangeDateLast>2017-11-30T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="26148" linkType="Company"&gt;EXIMIAS&lt;/ulink&gt; (formerly Zarix), under license from &lt;ulink linkID="26488" linkType="Company"&gt;Agouron&lt;/ulink&gt;, was developing an iv formulation of nolatrexed (nolatrexed dihydrochloride, Thymitaq), a thymidylate synthase inhibitor, for the potential treatment of cancer (the lead indication being unresectable hepatocellular carcinoma (HCC)). In September 2000, EXIMIAS began a  phase III trial of nolatrexed in combination with &lt;ulink linkID="7934" linkType="Drug"&gt;doxorubicin&lt;/ulink&gt;  for HCC in the US, Canada, South Africa and certain European countries [&lt;ulink linkID="382746" linkType="reference"&gt;382746&lt;/ulink&gt;], [&lt;ulink linkID="397955" linkType="reference"&gt;397955&lt;/ulink&gt;], [&lt;ulink linkID="406147" linkType="reference"&gt;406147&lt;/ulink&gt;]; in April 2005, recruitment was complete [&lt;ulink linkID="596017" linkType="Reference"&gt;596017&lt;/ulink&gt;]. In August 2005, data were reported from the phase III trial; nolatrexed failed to show greater survival benefit than doxorubicin, the study's primary endpoint. At that time, the trial data were to undergo further analysis   [&lt;ulink linkID="615904" linkType="Reference"&gt;615904&lt;/ulink&gt;]. In September 2003, phase I/II trials of nolatrexed in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt;   were initiated for the potential treatment of breast, lung, head and neck cancers in the US  [&lt;ulink linkID="505091" linkType="Reference"&gt;505091&lt;/ulink&gt;]; these trials were ongoing in December 2004  [&lt;ulink linkID="575028" linkType="Reference"&gt;575028&lt;/ulink&gt;].   However, &lt;ulink linkID="24845" linkType="Company"&gt;YM BioSciences&lt;/ulink&gt; acquired EXIMIAS in May 2006 [&lt;ulink linkID="682620" linkType="Reference"&gt;682620&lt;/ulink&gt;], and did not intend to continue development of any EXIMIAS programs [&lt;ulink linkID="662000" linkType="Reference"&gt;662000&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;EXIMIAS was also developing  &lt;ulink linkID="49438" linkType="Drug"&gt;an oral formulation of nolatrexed (Orataq)&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2000, nolatrexed was designated a Fast Track product for the treatment of unresectable HCC by the FDA [&lt;ulink linkID="364887" linkType="reference"&gt;364887&lt;/ulink&gt;], based on the Agouron phase II data and medical necessity [&lt;ulink linkID="405928" linkType="reference"&gt;405928&lt;/ulink&gt;] and in November 2001, the FDA awarded the Orphan Drug status for the treatment of HCC [&lt;ulink linkID="428043" linkType="reference"&gt;428043&lt;/ulink&gt;]. In October 2003, nolatrexed received EU Orphan status for the treatment of HCC [&lt;ulink linkID="508296" linkType="reference"&gt;508296&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000, EXIMAS  expected to file an NDA in 2002 [&lt;ulink linkID="367559" linkType="reference"&gt;367559&lt;/ulink&gt;]; however, in April 2001, this was postponed to the third quarter of 2003 [&lt;ulink linkID="405928" linkType="reference"&gt;405928&lt;/ulink&gt;].  By November 2002 and in January 2003, the NDA filing was slated for 2004 and a Priority Review status was anticipated [&lt;ulink linkID="469444" linkType="reference"&gt;469444&lt;/ulink&gt;], [&lt;ulink linkID="476511" linkType="reference"&gt;476511&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;Patient enrollment in a multicenter, multinational, pivotal phase III trial in patients with unresectable HCC, comparing nolatrexed to doxorubicin, was initiated in September 2000. Unresectable HCC was the first indication being pursued for FDA approval and the trial design was deemed acceptable in August 2000. It was anticipated that patient accrual would be completed within 24 months [&lt;ulink linkID="378514" linkType="reference"&gt;378514&lt;/ulink&gt;], [&lt;ulink linkID="384018" linkType="reference"&gt;384018&lt;/ulink&gt;], [&lt;ulink linkID="382746" linkType="reference"&gt;382746&lt;/ulink&gt;]. The multicenter study was to be conducted as a global program with sites in the US, Canada, Europe and South Africa. In January 2001, the Canadian Therapeutic Products Directorate indicated that the design of the phase III trial was acceptable. Zarix expected patient enrollment at Canadian clinical sites to begin in Spring 2001 [&lt;ulink linkID="397955" linkType="reference"&gt;397955&lt;/ulink&gt;], [&lt;ulink linkID="405928" linkType="reference"&gt;405928&lt;/ulink&gt;]. By April 2001, patient enrollment was underway in the US, Italy, Canada, Romania, South Africa and the UK. At that time, Zarix also expected to initiate trials in the Czech Republic and Germany in the near future and in Poland in the summer of 2001 [&lt;ulink linkID="406147" linkType="reference"&gt;406147&lt;/ulink&gt;]. By November 2002, 223 patients had been enrolled into this trial, called ETHECC, achieving 50% recruitment [&lt;ulink linkID="469444" linkType="reference"&gt;469444&lt;/ulink&gt;]. In January 2003, an independent DSMB unanimously recommended the continuation of this trial. The DSMB interim review of safety data was successfully completed in over 140 patients. At that time, the study was underway at nearly 70 sites in the US, Canada, Europe and South Africa [&lt;ulink linkID="476511" linkType="reference"&gt;476511&lt;/ulink&gt;]. In May 2003, a second recommendation was given by a DSMB to continue the phase III trial of nolatrexed. At that time, enrollment in the trial was expected to be completed by the end of 2003 [&lt;ulink linkID="490501" linkType="reference"&gt;490501&lt;/ulink&gt;]. In April 2005, recruitment was completed [&lt;ulink linkID="596017" linkType="Reference"&gt;596017&lt;/ulink&gt;]. In August 2005, data were reported from the phase III trial.  Nolatrexed failed to show greater survival benefit than doxorubicin. At that time, the trial data were to undergo further analysis to better understand the results of the survival analysis and decide the drug's future [&lt;ulink linkID="615904" linkType="Reference"&gt;615904&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2004, phase II data from a study comparing nolatrexed with doxorubicin were presented at the 40th ASCO meeting in New Orleans, LA. HCC patients (n = 54) were randomized to receive either nolatrexed (n = 37) or doxorubicin (n = 17). In the intent-to-treat population, the median survival was 19.8 and 14.8 weeks for nolatrexed and doxorubicin, respectively. In the evaluable population, the median survival for nalotrexed was 23.4 weeks compared to 15.4 weeks for doxorubicin [&lt;ulink linkID="546058" linkType="reference"&gt;546058&lt;/ulink&gt;]. Further data from this trial were presented at the 39th ASCO meeting in Chicago, IL, in June 2003. Patients with unresectable liver cancer had an 86 to 100% improvement in survival after treatment with nolatrexed for 6 months [&lt;ulink linkID="491843" linkType="reference"&gt;491843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2003, a phase I/II trial was initiated to evaluate the safety and efficacy of nolatrexed in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; in patients with advanced solid tumors unresponsive to prior therapy. The combination was to be tested in patients with breast, lung and head and neck cancers once a suitable dosage had been identified [&lt;ulink linkID="505091" linkType="reference"&gt;505091&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2003, phase II data on nolatrexed were reported at the 39th ASCO meeting in Chicago, IL. A total of 36 patients with metastatic pancreatic cancer were given a starting dose of nolatrexed of 795 mg/m2 as a continuous infusion administered over 5 days every 3 to 4 weeks; dose adjustments of 15 to 20% were allowed according to toxicity. Hematological toxicities &amp;gt;/ = to grade 3 included leukopenia (n = 13), neutropenia (n = 9) and thrombocytopenia (n = 11). From 28 patients who received &amp;gt;/= two cycles of therapy and were evaluable for response, there was one partial response, 16 cases of stable disease; median overall  survival was 5.1 months. It was recommended that further evaluation should include a randomized comparison with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; in this patient population [&lt;ulink linkID="491842" linkType="reference"&gt;491842&lt;/ulink&gt;], [&lt;ulink linkID="492301" linkType="reference"&gt;492301&lt;/ulink&gt;]. In June 2003, further data on nolatrexed were presented at the same meeting. Patients (n = 128) were given nolatrexed (725 or 795 mg/m2/day) as an infusion for 5 days during a 21-day cycle. Stable disease, complete or partial responses were noted in 41% of patients [&lt;ulink linkID="493255" linkType="reference"&gt;493255&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 1997, three trials had been conducted involving a total of 149 patients with HCC [&lt;ulink linkID="405928" linkType="reference"&gt;405928&lt;/ulink&gt;]. In two US phase II trials, patients with unresectable HCC treated with nolatrexed had a median survival (intent-to-treat) of over 23 weeks, compared to published survivals (intent-to-treat) of less than 15 weeks. Nolatrexed had no end-organ toxicity. Side effects were typical of other antimetabolites but were of shorter duration [&lt;ulink linkID="364887" linkType="reference"&gt;364887&lt;/ulink&gt;], [&lt;ulink linkID="405928" linkType="reference"&gt;405928&lt;/ulink&gt;]. In June 2003 results from one of these trials were presented at the 39th ASCO meeting in Chicago, IL. Nolatrexed was administered to 48 patients at 725 mg/m2/24 h as a continuous infusion for 5 days. From 37 patients evaluable for response, one (3%) achieved a positive response, 18 (48%) achieved stable disease, ten of whom (27%) remained stable for &amp;gt; 3 months. The major hematological toxicities were leukopenia (79%), neutropenia (75%), thrombocytopenia (65%), rash (71%), asthenia (65%), nausea (62%), fever (52%), vomiting (48%) anorexia (44%) and diarrhea (44%). Nolatrexed treated patients experienced a survival benefit of approximately 45% compared to the best results achieved in HCC patients treated with doxorubicin, extending median overall survival from approximately 14.8 weeks to 24 weeks [&lt;ulink linkID="491516" linkType="reference"&gt;491516&lt;/ulink&gt;], [&lt;ulink linkID="492293" linkType="reference"&gt;492293&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2002, EXIMIAS granted rights to &lt;ulink linkID="30057" linkType="Company"&gt;LG Life Sciences Ltd&lt;/ulink&gt; to distribute, market, and sell nolatrexed in the &lt;ulink linkID="28971" linkType="Company"&gt;Republic of Korea&lt;/ulink&gt;. Under the terms of the agreement, LG would have exclusive distribution rights in Korea and, upon approval, would market nolatrexed under its newly launched life sciences division [&lt;ulink linkID="470009" linkType="reference"&gt;470009&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 1999, Zarix (now EXIMIAS) licensed worldwide rights to nolatrexed from Agouron [&lt;ulink linkID="311213" linkType="reference"&gt;311213&lt;/ulink&gt;], which had previously been developing the drug in collaboration with Roche [&lt;ulink linkID="211844" linkType="reference"&gt;211844&lt;/ulink&gt;], [&lt;ulink linkID="270994" linkType="reference"&gt;270994&lt;/ulink&gt;]. Agouron discontinued development of nolatrexed, based on an interim analysis of phase II/III trials which showed that although the compound was effective as a single agent in head and neck and liver tumors, it was not sufficiently better than existing therapeutics to justify further development [&lt;ulink linkID="270994" linkType="reference"&gt;270994&lt;/ulink&gt;], [&lt;ulink linkID="211844" linkType="reference"&gt;211844&lt;/ulink&gt;]. However, in its efforts to complete the monitoring of these studies, Zarix discovered that a great majority of patients experienced stabilization of disease with nolatrexed treatment [&lt;ulink linkID="405928" linkType="reference"&gt;405928&lt;/ulink&gt;]. Zarix was to focus development efforts on the treatment of HCC, and was developing nolatrexed in an iv formulation for the treatment of HCC [&lt;ulink linkID="364887" linkType="reference"&gt;364887&lt;/ulink&gt;]. However, &lt;ulink linkID="24845" linkType="Company"&gt;YM BioSciences&lt;/ulink&gt; acquired EXIMIAS in May 2006 [&lt;ulink linkID="682620" linkType="Reference"&gt;682620&lt;/ulink&gt;], and did not intend to continue development of any EXIMIAS programs [&lt;ulink linkID="662000" linkType="Reference"&gt;662000&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;As of May 2003, there were insufficient data for an updated evaluation of this drug.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ion Niculescu-Duvaz, 2 Radcliffe Gardens, Carshalton, Surrey, UK&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;19 March 2001&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Thymitaq (&lt;ulink linkType="Drug" linkID="5565"&gt;nolatrexed&lt;/ulink&gt; dihydrochloride, AG-337), also known as 2-amino-5-(4'-thiopyridyl)-6-methyl-3H-quinazolin-4-one, is a lipophilic (logP 1.88, [&lt;ulink linkType="reference" linkID="403675"&gt;403675&lt;/ulink&gt;]; 3.5 [&lt;ulink linkType="reference" linkID="157124"&gt;157124&lt;/ulink&gt;]), non-polyglutamable thymidylate synthase inhibitor for the potential treatment of cancer. It has been developed and synthesized by Agouron Pharmaceuticals [&lt;ulink linkType="reference" linkID="403675"&gt;403675&lt;/ulink&gt;] and was licensed by Zarix. Its design was based on an analysis of the high-resolution (2.3 A) crystallographic spectra of the ternary complex of E coli thymidylate synthase (TS, EC 2.1.1.45), 5'-fluorodeoxyuridylate and a classical glutamate-containing folic acid analog. [&lt;ulink linkType="reference" linkID="403675"&gt;403675&lt;/ulink&gt;] An iterative cycle of compound synthesis, modeling and new crystal complexes led to the development of a series of 5-arylthioquinazolin-4-ones that were designed to access a hydrophobic cavity in the active site of the enzyme. Thymitaq, which belongs to this series, proved to be a potent inhibitor of TS [&lt;ulink linkType="reference" linkID="207410"&gt;207410&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250780"&gt;250780&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="403675"&gt;403675&lt;/ulink&gt;]. The drug is a solid hydrochloride salt (C14H12N4OS.2HCl) and was characterized by thermal analysis, Karl Fisher titrimetry, powder X-ray diffractometry, scanning electron microscopy and Fourier-transform infrared. [&lt;ulink linkType="reference" linkID="250776"&gt;250776&lt;/ulink&gt;] The drug is actually in phase III clinical trials in certain European countries and the US [&lt;ulink linkType="reference" linkID="382746"&gt;382746&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="397955"&gt;397955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The synthetic strategy was based on the displacement of a halogen at the position 5 of 2-amino-6-methyl-3H-quinazolin-4-one by various arylthio anions, utilizing the Ullmann reaction. The corresponding 2-amino-5-bromo-6-methyl-quinazolin-4-one was prepared from the commercially available anthranilic acid via the appropriate isatin. Opening this intermediate with methanol and reacting the product thus obtained with chloroformamidine at elevated temperature resulted in good yields of the desired compounds [&lt;ulink linkType="reference" linkID="403675"&gt;403675&lt;/ulink&gt;]. This strategy was originally utilized by Agouron, however, Zarix has since updated the process but no data on the novel approach are available [&lt;ulink linkType="reference" linkID="405924"&gt;405924&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;As a model for Thymitaq, ab initio studies of some amino residues' complexes with mercaptopyridine were also performed. [&lt;ulink linkType="reference" linkID="398631"&gt;398631&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A number of analogs were also designed and synthesized for SAR studies [&lt;ulink linkType="reference" linkID="331307"&gt;331307&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="331601"&gt;331601&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="403675"&gt;403675&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;Thymitaq is a direct, non-competitive, potent inhibitor of E coli TS (Ki = 49 nM), and of recombinant human TS (Ki = 11 nM) [&lt;ulink linkType="reference" linkID="403675"&gt;403675&lt;/ulink&gt;]. Thymitaq's cytotoxicity was completely neutralized by the addition of thymidine, confirming that TS was the sole site of action [&lt;ulink linkType="reference" linkID="154035"&gt;154035&lt;/ulink&gt;]. Thymitaq depleted thymidine-5'-triphosphate in treated cells and also depleted 2'-deoxyguanosine-5'-triphosphate, while the ribonucleotide pool was not significantly perturbed [&lt;ulink linkType="reference" linkID="250780"&gt;250780&lt;/ulink&gt;]. The compound facilitated 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) binding to monomeric TS. The binding of Thymitaq to dimeric TS (human) changes the enzyme's conformation, thereby preventing the binding of another nucleotide. Thymitaq's binding also inhibits TS by competition with methylene-tetrahydrofolate for other binding sites [&lt;ulink linkType="reference" linkID="203690"&gt;203690&lt;/ulink&gt;]. Folate depletion in vitro increases the sensitivity of colon cancer cells and squamous carcinoma cells of the head and neck to Thymitaq between 2- and 7-fold [&lt;ulink linkType="reference" linkID="398471"&gt;398471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Flow cytometry studies demonstrated that Thymitaq blocks cells in S phase, an effect reversed by thymidine [&lt;ulink linkType="reference" linkID="154035"&gt;154035&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="157124"&gt;157124&lt;/ulink&gt;]. The effects of Thymitaq were quickly reversed on removal of the drug, suggesting that there is a rapid influx and efflux from cells and no intracellular metabolism to derivatives with enhanced retention [&lt;ulink linkType="reference" linkID="250777"&gt;250777&lt;/ulink&gt;]. Thymitaq enters the cell by passive diffusion [&lt;ulink linkType="reference" linkID="250777"&gt;250777&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="278296"&gt;278296&lt;/ulink&gt;]. The potential advantage of this inhibitor is its lack of requirement for active uptake into the cells or for polyglutamation. While these two processes contribute to the antitumor activity of the classical antifolates, they are also involved in mechanisms of resistance (ie, tumors expressing low levels of reduced folate carrier or folate polyglutamyl synthase).&lt;/para&gt;&lt;para&gt;The compound proved to be active in vitro against L1210 murine leukemia (mean IC50 = 0.39 microM), mouse thymidine kinase-deficient L5178Y lymphoma (IC50 = 0.74 microM), human lymphoblastic leukemia CCRF-CEM (IC50 = 1.27 microM), human thymidine kinase-deficient colon adenocarcinoma (IC50 = 1.54 microM) human lymphoblastic leukemia CCRF-CEM (IC50 = 1.27 microM) and human colon adenocarcinoma (IC50 = 6.60 microM). The compound is also effective in cell lines that have either an impairment in the level of reduced folate carrier (L1210:1565) or a polyglutamation defect (L1210:RD1694) [&lt;ulink linkType="reference" linkID="157124"&gt;157124&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250777"&gt;250777&lt;/ulink&gt;]. Thymitaq and the level of TS activity (1 pM dTMP/h/mg protein = 1 unit) were measured in a panel of 16 human colon cancer cells. The IC50 of Thymitaq ranged from 1.3 microM (SW948 cells) to 5.3 microM (Colo320) and TS activity from 558 to 11726 U in 13 cell lines. For the other 3 cell lines (Colo 201, SW1116 and H630R10) the IC50 varied between 27 and 74 microM but the TS activity varied between 485 and 235000 U, showing no correlation. These data showed that TS activity is not the sole determinant for Thymitaq antitumor efficacy, with cellular uptake also being important [&lt;ulink linkType="reference" linkID="203685"&gt;203685&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250787"&gt;250787&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="398628"&gt;398628&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;According to the company, Thymitaq is more effective than 5-fluorouracil (5-FU), with less toxic side effects, and acts as a radiosensitizer at sub-toxic levels (10 microM) in cultured tumor cells. This property may improve efficacy in the treatment of head and neck, lung, colon, and prostate tumors, which are often suitable candidates for radiotherapy. Other properties of benefit are &lt;ulink linkType="Drug" linkID="5565"&gt;nolatrexed&lt;/ulink&gt;'s low incidence of susceptibility to multidrug resistance and its high lipophilicity [&lt;ulink linkType="reference" linkID="190064"&gt;190064&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results from a preclinical study conducted in collaboration with the department of radiation oncology, &lt;ulink linkType="Company" linkID="23945"&gt;Henry Ford Hospital&lt;/ulink&gt;, yielded encouraging data for Thymitaq. Pretreatment of HT-29 human colon carcinoma cells with non-toxic concentrations of Thymitaq (&amp;lt; 10 microM) for short periods (24 h) dramatically enhanced the radiation-induced cell killing (ratio = 1.7) [&lt;ulink linkType="reference" linkID="250795"&gt;250795&lt;/ulink&gt;]. In vivo experiments using L5178Y (TK-) murine lymphoma (implanted in DBA/2 mice) confirmed the radiosensitizing potential of Thymitaq. In these tests the tumor control rate reached 90% and the radiation dose modification after a single dose of irradiation was 2.5. The study suggests that Thymitaq may have utility as an enhancer of radiation therapy [&lt;ulink linkType="reference" linkID="250789"&gt;250789&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Resistance factors to Thymitaq determined in SW-1573/2R120 (possessing MDR phenotype independent of P-glycoprotein) and SW-1573/2R160 (expressing P-glycoprotein) cell lines showed values of 17 and 0.7, respectively. This indicated that resistance to Thymitaq is related to the enzyme [&lt;ulink linkType="reference" linkID="278743"&gt;278743&lt;/ulink&gt;]. Cell sublines (eg, HT1080) resistant to Thymitaq (HT1080 AG-337) showed an increase in TS activity as well as a structural alteration in the TS enzyme [&lt;ulink linkType="reference" linkID="250796"&gt;250796&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250788"&gt;250788&lt;/ulink&gt;]. The IC50 values were 12- to 40-fold greater than in the corresponding non-resistant cells. Studies have shown that TS gene amplification leading to mRNA and enzyme overproduction is a major mechanism of resistance to Thymitaq. However, in drug-resistant cell lines, differences in TS enzyme stability (with respect to the wild type) were noticed. The changes in TS polypeptide stability accompany and even contribute to acquired resistance to the drug [&lt;ulink linkType="reference" linkID="398622"&gt;398622&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In vivo experiments showed that Thymitaq exhibits antitumor activity against murine (thymidine kinase-deficient) transplanted tumors and against two human tumor xenograft lines. Using murine L5178Y (TK-) lymphoma implanted ip or im in DBA/2 mice 100% cures were obtained for the ip implanted tumors for a number of schedules. However, prolonged dosing periods of 5 to 10 days were required for activity and efficacy and these parameters were further improved by administration bid. A dose of 100 mg/kg ip was required to cure im implanted tumors. High oral bioavailability (90%) relative to ip delivery was reported for Thymitaq. Oral delivery required doses &amp;gt; 150 mg/kg bid for 5 to 10 days to produce 100% cure rates [&lt;ulink linkType="reference" linkID="154038"&gt;154038&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250777"&gt;250777&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Thymitaq exhibits a potent cytotoxic effect, which is greater than that of 5-fluorouracil (5-FU), on HT-29 colon and A2008 ovarian cancer cell lines (IC50 = 0.17 and 0.17 microM, respectively). The activity of the drug was not significantly affected in a 5-FU-resistant HT-29 subline characterized by an amplification of the TS gene [&lt;ulink linkType="reference" linkID="250774"&gt;250774&lt;/ulink&gt;]. A combination of Thymitaq and cisplatin exerted a synergistic activity in both ovarian and colon cancer cell lines, even in those resistant to 5-FU [&lt;ulink linkType="reference" linkID="250774"&gt;250774&lt;/ulink&gt;] and a synergistic antiproliferative effect was observed in vitro when Thymitaq was combined with &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;. Synergistic effects were maintained in the 5-FU resistant cells. Synergy was also observed in vivo in a GR mouse mammary tumor model [&lt;ulink linkType="reference" linkID="206613"&gt;206613&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="276795"&gt;276795&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A preclinical study on the human hepatoma cell line, Hep3B, demonstrated the synergistic effect of combining radiolabeled iododeoxyuridine ((125I)-dUrd) and Thymitaq in clonogenic assays. In vivo incorporation effects following the loco-regional delivery of both drugs confirmed in vitro studies and showed a dose-dependent modulation of Thymitaq on the DNA-[125I]dUrd incorporation. Studies on a rat N1S1 hepatoma model demonstrated superior therapeutic effects of the combination of Thymitaq and [125I]dUrd in both subcutaneous and ascite models [&lt;ulink linkType="reference" linkID="362701"&gt;362701&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Dipyridamole, which acts by inhibiting nucleoside transport [&lt;ulink linkType="reference" linkID="339043"&gt;339043&lt;/ulink&gt;], and one of its derivatives, &lt;ulink linkType="Drug" linkID="16470"&gt;NU-3076&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="21243"&gt;The University of Newcastle Upon Tyne&lt;/ulink&gt;), potentiated the cytotoxicity of Thymitaq in L1210 leukemia cells, with both compounds reducing the the LC90 by 3-fold in the absence of salvageable thymidine. Thymidine rescue from the drug was partially blocked by both derivatives at a 1 microM concentration. &lt;/para&gt;&lt;para&gt;A 7-fold upregulation of TS protein was observed during treatment with Thymitaq. Elevation of TS persisted up to 12 h after removal of the drug and the extent of induction did not depend on basal TS levels. In vivo experiments using L55178Y (TK-) tumors in DBA/2 mice also showed greater upregulation of TS protein in normal intestinal epithelial cells compared with tumor cells [&lt;ulink linkType="reference" linkID="398467"&gt;398467&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Thymitaq inhibits both bone marrow cell proliferation in suspension cultures and colony formation by maturer progenitor cells (CFU-C) in clonogenic assays. However, at high concentration the compound is unique in displaying irreversible cytotoxicity toward CFU-C progenitors by totally abolishing colony formation [&lt;ulink linkType="reference" linkID="398479"&gt;398479&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data presented at the 88th AACR meeting in April 1997 (San Diego), demonstrated the ability of Thymitaq to induce time-dependent cytotoxic effects involving the apoptotic pathway. This may help to elucidate the role of apoptosis in cell death due to TS inhibition. Other studies are attempting to elucidate the role of mitochondrial function and intracellular calcium mobilization during apoptosis, and the potential influence on these mechanisms by DNA strand breaks and the expression of p53, bcl-2 and bax [&lt;ulink linkType="reference" linkID="244965"&gt;244965&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Thymitaq-induced cell death via TS inhibition, in L1210 (p53 mutants) and HL60 (p53 null) cells, is mediated via the apoptotic pathway, which involves biphasic alteration in the mitochondrial membrane potential. In L1210 but not in HL60 cells, caspases function as the final executioner of apoptosis. In vitro data for Thymitaq in a number of cell lines were presented at the American Association for Cancer Research 91st Annual Meeting in April 2000. The compound has IC50 values of 3.6, 1.3, 6.5 and 1.7 microM for L1210, HL60, HCT116 and HT29 cells, respectively; cell death was mediated by apoptosis. The role of caspase activation in Thymitaq-induced apoptosis occurred downstream of any mitochondrial changes [&lt;ulink linkType="reference" linkID="361864"&gt;361864&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="398476"&gt;398476&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A study performed in a number of colon cell lines indicated that the p53 status and, possibly, bcl-2 are important factors for the induction of apoptosis by Thymitaq [&lt;ulink linkType="reference" linkID="294223"&gt;294223&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A model of drug-resistance gene therapy has been developed in vitro, using E coli TS (intrinsically more resistant to TS-directed inhibitors). The study showed that retroviral transfer of E coli TS confers high-level resistance to transduced bone marrow cells at concentration of Thymitaq which completely eliminate the non-transfected progenitors [&lt;ulink linkType="reference" linkID="398465"&gt;398465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;High doses of Thymitaq were well tolerated in dogs. Single-dose treatment by 24-h infusions of up to 200 mg/kg has been achieved without lethality [&lt;ulink linkType="reference" linkID="154035"&gt;154035&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;The pharmacokinetics and tumor distribution of Thymitaq were studied in rats. Following a 25 mg/kg/h iv bolus dose, the following parameters were obtained: terminal half-life (t1/2) = 1.3 h, systemic clearance (Cls) = 0.7 l/kg and volume of distribution = 0.5 l/kg. Tissue distribution studies with (14C)-Thymitaq at 30 min post-administration showed the highest level of drug in kidney (73 microg/g), liver (40 microg/g), small intestine (29 microg/g) and lungs (16 microg/g). The levels in other organs were similar to that in plasma (12 microg/g). A significant amount of Thymitaq was excreted in urine (59%) and feces (16%). The compound does not cross the blood-brain barrier [&lt;ulink linkType="reference" linkID="154036"&gt;154036&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The pharmacokinetics in rats after iv administration are best described by a two-compartmental model (t1/2alpha = 0.042 h, t1/2beta = 1.98 h and AUC = 107.5 microM.h) and were dose-independent between 25 and 100 mg/kg. An elimination t1/2 of 2 h was determined. The volume of distribution was 1.36 l/kg as expected for a lipophilic compound and systemic clearance was 0.53 l/kg. Oral bioavailability was demonstrated in the rat and was greater in fasted animals (53% by iv delivery) than fed animals (22%). After oral administration the t1/2 was 2.92 h and oral bioavailability by ip delivery varied from 62 to 90% [&lt;ulink linkType="reference" linkID="250777"&gt;250777&lt;/ulink&gt;]. The absortion of Thymitaq in the rat intestine proceeds mainly via a purine-base carrier with an important non-saturable component [&lt;ulink linkType="reference" linkID="398642"&gt;398642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I &lt;/subtitle&gt;Thymitaq entered clinical trials at Newcastle General Hospital in the UK in November 1992. The maximum dose was 1073 mg/m2/day, administered by continuous infusion for 24-h duration. No systemic toxicity was encountered, but grade 2 phlebitis was reported [&lt;ulink linkType="reference" linkID="398623"&gt;398623&lt;/ulink&gt;]. An MTD was not reached [&lt;ulink linkType="reference" linkID="405928"&gt;405928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I clinical study comprising a 24-h continuous infusion of Thymitaq every 3 weeks was completed in 13 patients with advanced solid tumors. The doses ranged between 75 (0.1-fold mouse LD10) and 1350 mg/m2 [&lt;ulink linkType="reference" linkID="157402"&gt;157402&lt;/ulink&gt;]. At 1350 mg/m2, a plasma concentration of 10 to 15 microg/ml was achieved for the 5 days and 18 h following termination of the infusion, declining with a mean t1/2 of 134 +/- 62 min. There was a linear relationship between the dose and the AUC of Thymitaq. The mean urinary excretion between 0 to 48 h was 17 +/- 6% of the administered dose. Plasma deoxyuridine (UdR) increased 60 to 390%, demonstrating that TS-inhibitory levels of Thymitaq had been achieved [&lt;ulink linkType="reference" linkID="157402"&gt;157402&lt;/ulink&gt;]. Clearance decreased from 190 to 85 ml/min/m2 between the lowest and the highest dose, indicating non-linear pharmacokinetics. A linear, single-compartment model adequately described data at doses up to 300 mg/m2, while at doses &amp;gt; 600 mg/m2, a model with Michaelis-Menten elimination provided a better fit to the data [&lt;ulink linkType="reference" linkID="174880"&gt;174880&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Based on further preclinical evaluation, a 5-day, 24-h continuous infusion schedule was utilized at doses between 120 and 1300 mg/m2/day. Data from all but the lower doses required a single- or double-compartment model with Michaelis Menten elimination [&lt;ulink linkType="reference" linkID="174880"&gt;174880&lt;/ulink&gt;]. Dose-limiting toxicities (DLTs) were myelosuppression and mucositis. Data from 21 patients (47 courses) treated with doses ranging from 120 to 1300 mg/m2/day for 5 days showed that the relationship between toxicity and dose or AUC could be described by a sigmoid Emax model with a closer correlation being observed for AUC. There was a dose-dependent decrease in plasma Thymitaq clearance, indicating a saturable elimination [&lt;ulink linkType="reference" linkID="207491"&gt;207491&lt;/ulink&gt;]. Antiproliferative toxicities were observed when plasma UdR elevations were maintained for 5 days [&lt;ulink linkType="reference" linkID="203669"&gt;203669&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="207491"&gt;207491&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase I interim data from the UK, evaluating &lt;ulink linkType="Drug" linkID="5565"&gt;nolatrexed&lt;/ulink&gt; in children with advanced malignancies, has shown that plasma pharmacokinetics were comparable to those at similar dose levels in the adult phase I study, when the agent was administered as a continuous 5-day iv infusion. [&lt;ulink linkType="reference" linkID="242500"&gt;242500&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Thymitaq was administered, as a continuous 5-day iv infusion every 28 days, to children with relapsed leukemia and solid tumors involving the bone marrow. The doses ranged between 480 to 768 mg/m2/day. Of the patients (n = 16) who entered the trial, 11 were evaluable for toxicity. DLTs occurred at 768 mg/m2/day with 2/6 patients developing grade 4 oral mucositis, and 1/6 developing grade 4 thrombocytopenia and hepatic toxicity [&lt;ulink linkType="reference" linkID="250790"&gt;250790&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="288987"&gt;288987&lt;/ulink&gt;]. A 50% reduction in the peripheral blast count was found in all the patients at the end of the 5-day infusion. The pharmacokinetic data were in good agreement with data obtained for adults [&lt;ulink linkType="reference" linkID="250790"&gt;250790&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="288987"&gt;288987&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A study of 10-day continuous infusion of Thymitaq was initiated in ambulatory patients with advanced solid tumors because of preclinical data indicating that more prolonged exposure could be advantageous. Doses between 360 mg/m2 for 10 days, 572 mg/m2 for 10 days and 716 mg/m2 for 5, 7 and 8 days were used before toxicity occurred. Toxicities at 716 mg/m2/day for the planned 10 days were mild and included grade 2 leukopenia, mucositis, fatigue, skin rash and constipation. The infusions were terminated early due to thrombosis of the venous access device [&lt;ulink linkType="reference" linkID="405928"&gt;405928&lt;/ulink&gt;]. Plasma levels were evaluated in a number of patients and t1/2 values of 2.5 +/- 0.9 h, clearances of 8.3 to 21.3 l/h and AUC values of 336 to 720 microg/ml.h were reported. The rate of thrombosis provided evidence for not proceeding with this 10-day schedule [&lt;ulink linkType="reference" linkID="203667"&gt;203667&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="405928"&gt;405928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I clinical trial and pharmacokinetic study was initiated with Thymitaq in combination with cisplatin in patients with advanced solid tumors. Thymitaq was administered as 5-day continuous infusion in combination with cisplatin, which was given on day 1 as an iv infusion over 60 min, repeated every 28 days. The doses ranged from 556.5 to 636 mg/m2/day (free base) in combination with 75 to 100 mg/m2 cisplatin. The trial involved 14 patients and drug-related cytotoxicities included nausea, vomiting, asthenia and thrombocytopenia, which is dose limiting. Thymitaq's pharmacokinetic parameters appeared to be similar to those obtained when Thymitaq was given as a single agent. [&lt;ulink linkType="reference" linkID="289245"&gt;289245&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The pharmacokinetic interaction of Thymitaq and paclitaxel was studied in a phase I clinical trial in patients with advanced solid tumors. This combination was investigated because of the strong inhibitory effect exerted by Thymitaq on CYP3A4, the enzyme involved in paclitaxel metabolism. The metabolism and, hence, clearance of paclitaxel was impaired approximately 2-fold by Thymitaq. The proper placement of paclitaxel in the combination therapy was determined without unusual toxicity and no interference of paclitaxel metabolism. [&lt;ulink linkType="reference" linkID="294324"&gt;294324&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="405928"&gt;405928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The oral formulation has &amp;gt; 95% bioavailability. In a phase I clinical trial (n = 24 patients), Thymitaq was administered qid orally, as a 5-day course with doses ranging between 360 and 1250 mg/m2/day. The maximum tolerated dose (MTD) was 1250 mg/m2/day and the DLTs were nausea and vomiting. The recommended dose for phase II trials is 1000 mg/m2/day [&lt;ulink linkType="reference" linkID="207493"&gt;207493&lt;/ulink&gt;]. An alternative phase I study that used the same administration schedule was performed on 45 patients. The doses ranged from 288 to 1000 mg/m2/day. The DLTs were gastrointestinal and the recommended phase II oral dose was 800 mg/m2/day [&lt;ulink linkType="reference" linkID="398636"&gt;398636&lt;/ulink&gt;]. These data were confirmed by a phase I study, which showed that the maximum tolerated dose for oral administration on a 5-day schedule is 1250 mg/m2/day. At 1000 mg/m2/day, the plasma concentration of the drug ranged from 12 to 18 microg/ml [&lt;ulink linkType="reference" linkID="203668"&gt;203668&lt;/ulink&gt;]. The pharmacokinetic data obtained in a phase I trial of Thymitaq administered orally to fed and fasted patients showed no significant differences [&lt;ulink linkType="reference" linkID="250785"&gt;250785&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I clinical trial, Thymitaq was administered orally every 6 h for 10 days (3-weekly cycle) to 15 patients with metastatic colon cance. Doses were escalated from 100 to 720 mg/m2/day. Grade 3 toxicities included nausea and vomiting, anorexia, fatigue and stomatitis. Thrombocytopenia (grade 2) was observed at 720 mg/m2/day. Thymitaq plasma concentration were in the range of 10 to 14 microg/ml (1 h post-administration) and 2 to 3 microg/ml (6 h post-administration) at a dose of 540 mg/m2/day [&lt;ulink linkType="reference" linkID="203670"&gt;203670&lt;/ulink&gt;]. Similar data were obtained in a phase I study in 23 patients, in which Thymitaq was also administered orally according to a 10-day schedule. The doses ranged from 80 to 572 mg/m2/day [&lt;ulink linkType="reference" linkID="398623"&gt;398623&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The thymidine salvage pathway was activated in tissues following treatment with Thymitaq. Positron emission tomography (PET) was used to investigate this effect [&lt;ulink linkType="reference" linkID="250786"&gt;250786&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;Encouraging interim results from six phase II studies of &lt;ulink linkType="Drug" linkID="5565"&gt;nolatrexed&lt;/ulink&gt; in patients with solid tumors associated with cancer of head and neck, pancreas, prostate, hepatoma, colon and non-small cell lung cancer were presented at the American Association for Cancer Research (AACR) meeting, 1996. Interim results of these phase II trials were also presented at the Hambrecht &amp;amp; Quist Health Care Conference, January 1996. In addition, out of 41 evaluable patients with cancers of the pancreas, prostate and colon regressions of less than 50% or stable disease were observed in 32 patients [&lt;ulink linkType="reference" linkID="195211"&gt;195211&lt;/ulink&gt;]. In addition, preliminary results from these phase II trials were presented at the AACR in Florida in November 1995 [&lt;ulink linkType="reference" linkID="191914"&gt;191914&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Ten institutions in the US participated in phase II clinical trials of Thymitaq involving the following cancer localizations: head and neck (H+N), pancreas, prostate, hepatocellular (HCC), colon and non-small cell lung (NSCLC) cancer. Thymitaq was administered as a 5-day infusion repeated every 3 weeks, starting with 1000 mg/m2/day. Patients were evaluable for disease response if they experienced grade 2 toxicity and received a subsequent course of treatment. A total of 78 patients were evaluated: H+N (n = 12), pancreas (n = 15), prostate (n = 8), HCC (n = 13), colon (n = 15) and NSCLC (n = 15). Four H+N patients showed objective responses. Among the HCC patients, one achieved a partial response (PR) and several had minor reductions in tumors followed by surgical resection or stable disease. Four patients with pancreas cancer showed stable disease. According to this survey Thymitaq appears to be active in H+N and HCC and may contribute to disease stabilization [&lt;ulink linkType="reference" linkID="203671"&gt;203671&lt;/ulink&gt;]. A continuation of this study showed two complete responses (CRs) and two PRs in 14 evaluable H+N patients [&lt;ulink linkType="reference" linkID="207482"&gt;207482&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II studies conducted in the treatment of HCC, a total of 90 patients with advanced unresectable HCC were treated with Thymitaq at 725mg/m2/day given as a 5-day continuous infusion. Of the 75 patients evaluable for efficacy (CR, PR, SD), only 2 patients had a PR and 34 had stable disease for .3 months. The median survivals for all patients in their respective studies are summarized below. The patient populations were not equal in that the criteria for cessation of treatment varied from study to study and the inclusion /exclusion criteria were different. [&lt;ulink linkType="reference" linkID="294578"&gt;294578&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="405928"&gt;405928&lt;/ulink&gt;]. These results were confirmed by more recent data from a cohort of 28 patients, in which two PRs (8%), two minor responses (8%) were observed and 14 patients (54%) achieved stable disease [&lt;ulink linkType="reference" linkID="398630"&gt;398630&lt;/ulink&gt;]. The conclusion was that Thymitaq has activity that is not measurable by objective tumor respose primarily due to the clinical setting of the disease making measurements difficult and provides at least a 50% improvement in survival over all other forms of sinngle agent therapy for HCC [&lt;ulink linkType="reference" linkID="405928"&gt;405928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II randomized (2:1) study conducted in Hong Kong compared the efficacy of Thymitaq to doxorubicin in 60 patients with unresectable HCC. The median survival for the Thymitaq-treated patients was 22.6 weeks while the doxorubicin group had a median survival of 12.9 weeks. Many patients in both arms were taken off-study when there was a failure to show an objective response and dosages were liberally adjusted downward. It was concluded that the efficacies of both drugs in HCC patients were lower than that found in the non-randomized Thymitaq trials (23.8 and 23.5 weeks) and that reported in nine published doxorubicin trials in which survival was determined for all patients enrolled in the studies (intent-to-treat) 15.9 weeks. For these reasons, the FDA approved the fast track for Thymitaq and the adopted program that is underway [&lt;ulink linkType="reference" linkID="294610"&gt;294610&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="405928"&gt;405928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Patient enrollment in a multicenter, pivotal, phase III trial in patients with unresectable HCC comparing Thymitaq to doxorubicin was initiated in September 2000 [&lt;ulink linkType="reference" linkID="378514"&gt;378514&lt;/ulink&gt;] but no data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;In phase I studies, DLTs included myelosuppression, mucositis, thrombocytopenia, hepatic toxicity nausea and vomiting. [&lt;ulink linkType="reference" linkID="207491"&gt;207491&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="207493"&gt;207493&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="250790"&gt;250790&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="288987"&gt;288987&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a multicenter phase II study in the US, DLTs included neutropenia, thrombocytopenia, stomatitis and skin rashes. Hematological toxicities were characterized by rapid recovery and the rare need for transfusions or growth factors. Other adverse events included anemia, diarrhea, nausea, vomiting, fatigue, anorexia, alopecia, hand-foot syndrome (palm and sole peeling and skin hyperpigmentation) and an altered sense of taste [&lt;ulink linkType="reference" linkID="203671"&gt;203671&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="405928"&gt;405928&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Thymitaq is a lipophilic, non-polyglutamable, potent TS inhibitor (Ki = 11 nM in human TS) that exhibits non-competitive inhibition kinetics with the enzyme. The drug rapidly inhibits TS and the thymidine triphosphate pool (TTP) but recovery after extracellular drug removal is relatively quick. Thymitaq enters the cell by passive diffusion and it is expected that classical antifolate resistance mechanisms involving defective cellular membrane transport and polyglutamation will not influence Thymitaq's activity. The drug arrests the cell cycle in S phase and its action is reversed by thymidine.&lt;/para&gt;&lt;para&gt;Curative antitumor activity in mouse ip and im implanted L5178Y (TK-) lymphoma and also significant growth inhibition against a panel of human tumor xenograft were reported, both effects being dose-dependent. Antitumor studies both in vitro and in vivo suggested that &amp;gt; 24-h continuous exposure was required to induce cytotoxic effects. Phase I pharmacokinetic studies showed suitable kinetic parameters. Rapid plasma clearance (t1/2 &amp;lt; 2 h) was observed after infusion termination. Therefore, the drug should be administered by 5- or 10-day continuous infusions. &lt;br/&gt;An advantage of Thymitaq is that it shows an oral bioavailability of &amp;gt; 90%. This prompted a number of phase I trials utilizing oral administration. The pharmacokinetic parameters obtained during these trials were comparable with those obtained during iv infusions. &lt;/para&gt;&lt;para&gt;The compound is well tolerated with DLTs of myelosuppression and stomatitis. Other transient toxicities include anemia, fatigue, nausea, vomiting, diarrhoea, anorexia, alopecia, skin hyperpigmentation and altered sense of taste.&lt;/para&gt;&lt;para&gt;Phase II clinical trials indicated activity in a broad range of tumors, producing stable disease more often than producing CRs or PRs. Thymitaq showed demonstrated an improvement in survival over all other single agents, including doxorubicin, against HCC. According its biochemical profile it could be useful as a second-line treatment in tumors resistant to classical antifolates. Another advantage could be its radiosensitizing effect. However, no clinical data are available supporting these possibilities are currently available. A large phase III clinical trial is in progress.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26148">YM BioSciences USA</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="682620" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26148">YM BioSciences USA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="682620" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26148">YM BioSciences USA</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="682620" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="767">Colon tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26148">YM BioSciences USA</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="682620" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26148">YM BioSciences USA</Company><Country id="RO">Romania</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="682620" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="767">Colon tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26148">YM BioSciences USA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="682620" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26148">YM BioSciences USA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="682620" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26148">YM BioSciences USA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-05-09T00:00:00.000Z</StatusDate><Source id="682620" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><Source id="175016" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><Source id="175016" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><Source id="175016" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><Source id="175016" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><Source id="175016" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="767">Colon tumor</Indication><Source id="175016" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><Source id="175044" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><Source id="175044" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-07T00:00:00.000Z</StatusDate><Source id="397955" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-18T00:00:00.000Z</StatusDate><Source id="406147" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="RO">Romania</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-18T00:00:00.000Z</StatusDate><Source id="406147" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-18T00:00:00.000Z</StatusDate><Source id="406147" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-09-25T00:00:00.000Z</StatusDate><Source id="382746" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-02-07T00:00:00.000Z</StatusDate><Source id="397955" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-01-12T00:00:00.000Z</StatusDate><Source id="311213" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-09-16T00:00:00.000Z</StatusDate><Source id="505091" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="270994" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="271033" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="271033" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="271033" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26488">Agouron Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1997-12-03T00:00:00.000Z</StatusDate><Source id="271033" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-10-01T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26148">YM BioSciences USA</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-09-18T00:00:00.000Z</StatusDate><Source id="364887" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="623">Head and neck tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-26T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-26T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-26T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="755">Lung tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-26T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-26T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="767">Colon tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-26T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-26T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26178">F Hoffmann-La Roche AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-06-26T00:00:00.000Z</StatusDate><Source id="211844" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="26148">YM BioSciences USA</OwnerCompany><Country id="US">US</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of unresectable HCC</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-05-02T00:00:00.000Z</MileStoneDate><Source id="364887" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26148">YM BioSciences USA</OwnerCompany><Country id="US">US</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26148">YM BioSciences USA</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-10-02T00:00:00.000Z</MileStoneDate><Source id="508296" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26148">YM BioSciences USA</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-07-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26148">YM BioSciences USA</OwnerCompany><Country id="US">US</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-10-18T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01852"><Name>Thymidylate synthase</Name><SwissprotNumbers><Swissprot>O26868</Swissprot><Swissprot>O30394</Swissprot><Swissprot>O30397</Swissprot><Swissprot>O33380</Swissprot><Swissprot>O62584</Swissprot><Swissprot>O66108</Swissprot><Swissprot>O76511</Swissprot><Swissprot>O96650</Swissprot><Swissprot>P00469</Swissprot><Swissprot>P00471</Swissprot><Swissprot>P04818</Swissprot><Swissprot>P06785</Swissprot><Swissprot>P06854</Swissprot><Swissprot>P07606</Swissprot><Swissprot>P07607</Swissprot><Swissprot>P09249</Swissprot><Swissprot>P0A0M5</Swissprot><Swissprot>P0A884</Swissprot><Swissprot>P0A885</Swissprot><Swissprot>P0A886</Swissprot><Swissprot>P0C0M4</Swissprot><Swissprot>P0C0M5</Swissprot><Swissprot>P11044</Swissprot><Swissprot>P12461</Swissprot><Swissprot>P12462</Swissprot><Swissprot>P13100</Swissprot><Swissprot>P19368</Swissprot><Swissprot>P44420</Swissprot><Swissprot>P45352</Swissprot><Swissprot>P47469</Swissprot><Swissprot>P48464</Swissprot><Swissprot>P54081</Swissprot><Swissprot>P57515</Swissprot><Swissprot>P57808</Swissprot><Swissprot>P59427</Swissprot><Swissprot>P67042</Swissprot><Swissprot>P67043</Swissprot><Swissprot>P67045</Swissprot><Swissprot>P67046</Swissprot><Swissprot>P67047</Swissprot><Swissprot>P67048</Swissprot><Swissprot>P67049</Swissprot><Swissprot>P67050</Swissprot><Swissprot>P67051</Swissprot><Swissprot>P67052</Swissprot><Swissprot>P78029</Swissprot><Swissprot>P80305</Swissprot><Swissprot>P90463</Swissprot><Swissprot>Q4QM04</Swissprot><Swissprot>Q57931</Swissprot><Swissprot>Q59212</Swissprot><Swissprot>Q5D189</Swissprot><Swissprot>Q5E7P1</Swissprot><Swissprot>Q5FKL6</Swissprot><Swissprot>Q5GWB5</Swissprot><Swissprot>Q5HFZ6</Swissprot><Swissprot>Q5HMP6</Swissprot><Swissprot>Q5KZ25</Swissprot><Swissprot>Q5M0S7</Swissprot><Swissprot>Q5M5B3</Swissprot><Swissprot>Q5NFK5</Swissprot><Swissprot>Q5P233</Swissprot><Swissprot>Q5PEN6</Swissprot><Swissprot>Q5R064</Swissprot><Swissprot>Q5WDS1</Swissprot><Swissprot>Q5WSU5</Swissprot><Swissprot>Q5X119</Swissprot><Swissprot>Q5XCM3</Swissprot><Swissprot>Q5YPL7</Swissprot><Swissprot>Q5ZRL3</Swissprot><Swissprot>Q603S2</Swissprot><Swissprot>Q63BV5</Swissprot><Swissprot>Q64PV5</Swissprot><Swissprot>Q65J44</Swissprot><Swissprot>Q65VJ8</Swissprot><Swissprot>Q667F9</Swissprot><Swissprot>Q67JQ1</Swissprot><Swissprot>Q6A761</Swissprot><Swissprot>Q6AFI0</Swissprot><Swissprot>Q6D8I6</Swissprot><Swissprot>Q6F145</Swissprot><Swissprot>Q6FER7</Swissprot><Swissprot>Q6FZ91</Swissprot><Swissprot>Q6G2S8</Swissprot><Swissprot>Q6G9D4</Swissprot><Swissprot>Q6GGY0</Swissprot><Swissprot>Q6HJC7</Swissprot><Swissprot>Q6KIQ6</Swissprot><Swissprot>Q6LUM1</Swissprot><Swissprot>Q6MID2</Swissprot><Swissprot>Q6N447</Swissprot><Swissprot>Q6NIF2</Swissprot><Swissprot>Q6REU8</Swissprot><Swissprot>Q6YQT0</Swissprot><Swissprot>Q71YE1</Swissprot><Swissprot>Q738X7</Swissprot><Swissprot>Q73VZ2</Swissprot><Swissprot>Q74IU3</Swissprot><Swissprot>Q7MNN6</Swissprot><Swissprot>Q7MTB5</Swissprot><Swissprot>Q7N8U4</Swissprot><Swissprot>Q7NZ95</Swissprot><Swissprot>Q7UID0</Swissprot><Swissprot>Q7VMH2</Swissprot><Swissprot>Q7VUE3</Swissprot><Swissprot>Q7W1A9</Swissprot><Swissprot>Q7WP13</Swissprot><Swissprot>Q81E05</Swissprot><Swissprot>Q81R23</Swissprot><Swissprot>Q82WU3</Swissprot><Swissprot>Q834R3</Swissprot><Swissprot>Q83BG2</Swissprot><Swissprot>Q87BT4</Swissprot><Swissprot>Q87SA0</Swissprot><Swissprot>Q87UL4</Swissprot><Swissprot>Q88CN9</Swissprot><Swissprot>Q88W05</Swissprot><Swissprot>Q89940</Swissprot><Swissprot>Q89G35</Swissprot><Swissprot>Q8A639</Swissprot><Swissprot>Q8D2N4</Swissprot><Swissprot>Q8DER9</Swissprot><Swissprot>Q8DUI4</Swissprot><Swissprot>Q8DZ07</Swissprot><Swissprot>Q8E4L6</Swissprot><Swissprot>Q8EH94</Swissprot><Swissprot>Q8EQG0</Swissprot><Swissprot>Q8EV81</Swissprot><Swissprot>Q8FR47</Swissprot><Swissprot>Q8G3T9</Swissprot><Swissprot>Q8K9C3</Swissprot><Swissprot>Q8NS38</Swissprot><Swissprot>Q8P1D1</Swissprot><Swissprot>Q8PCE7</Swissprot><Swissprot>Q8PP46</Swissprot><Swissprot>Q8PXI1</Swissprot><Swissprot>Q8RGP6</Swissprot><Swissprot>Q8SRG2</Swissprot><Swissprot>Q8THH4</Swissprot><Swissprot>Q8TVL9</Swissprot><Swissprot>Q8UDS3</Swissprot><Swissprot>Q8Y0U6</Swissprot><Swissprot>Q8Y626</Swissprot><Swissprot>Q8Z412</Swissprot><Swissprot>Q8ZHV1</Swissprot><Swissprot>Q8ZMA9</Swissprot><Swissprot>Q92AD4</Swissprot><Swissprot>Q92NQ5</Swissprot><Swissprot>Q97EV3</Swissprot><Swissprot>Q98KH9</Swissprot><Swissprot>Q98Q31</Swissprot><Swissprot>Q9A6H0</Swissprot><Swissprot>Q9ANR7</Swissprot><Swissprot>Q9CBW0</Swissprot><Swissprot>Q9I6F1</Swissprot><Swissprot>Q9JT57</Swissprot><Swissprot>Q9JY72</Swissprot><Swissprot>Q9K7B5</Swissprot><Swissprot>Q9P4T7</Swissprot><Swissprot>Q9PB13</Swissprot><Swissprot>Q9RAM7</Swissprot><Swissprot>Q9XC19</Swissprot><Swissprot>Q9Z671</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="16450">Gilead Sciences Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22235">LG Chem Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>2</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1ccc2c(c1Sc3ccncc3)c(=O)[nH]c(n2)N.Cl.Cl</Smiles><Smiles>Cc1ccc2c(c1Sc3ccncc3)c(=O)nc([nH]2)N</Smiles></StructureSmiles><Deals><Deal id="112911" title="Agouron and Roche to codevelop cyclin-dependent kinase inhibitors  "></Deal><Deal id="113142" title="Eximias Pharmaceutical to develop and commercialize Agouron's nolatrexed worldwide"></Deal><Deal id="115466" title="LG Life Sciences to market nolatrexed in Korea from EXIMIAS"></Deal></Deals><PatentFamilies><PatentFamily id="1026245" number="CN-01857215" title="Slow released injection containing antimetabolite"></PatentFamily><PatentFamily id="1257585" number="CN-101353343" title="Method for preparing the high purity nolatrexed dihydrochloride dihydrate"></PatentFamily><PatentFamily id="1390732" number="WO-09320055" title="Antiproliferative quinazolines."></PatentFamily><PatentFamily id="1403202" number="CN-101416938" title="Slow-release injection containing nolatrexed and its synergistic agent"></PatentFamily><PatentFamily id="1692790" number="CN-01857209" title="Slow released anticancer injection containing antimetabolite"></PatentFamily><PatentFamily id="1903612" number="CN-100348194" title="Lipid formulation of nolatrexed dihydrochloride and its preparation method"></PatentFamily><PatentFamily id="1988606" number="CN-01857211" title="Slow released injection containing nolatrexed and its synergist"></PatentFamily><PatentFamily id="2136665" number="CN-01857212" title="Slow released anticancer injection containing antimetabolite and cellular poison medicine"></PatentFamily><PatentFamily id="286527" number="CN-01857214" title="Slow released anticancer injection with both antimetabolite and cellular poison medicine"></PatentFamily><PatentFamily id="3118750" number="CN-105232476" title="Preparation method of hydrochloride freeze-dried powder injection"></PatentFamily><PatentFamily id="3714783" number="CN-106831715" title="Nolatrexed dihydrochloride crystal form ii, preparation method and application thereof"></PatentFamily><PatentFamily id="63940" number="CN-01857213" title="Slow released anticancer injection with both antimetabolite and cellular poison medicine"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>9</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Healthstar Medical Development Co Ltd" id="1038909"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Konruns Pharmaceutical Co Ltd" id="1053225"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China National Pharmaceutical Group Corporation" id="1055632"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Lanjin Pharmaceuticals Co Ltd" id="1069185"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Konruns Pharmaceutical Co Ltd" id="1140059"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>